On January 2, 2024 AbbVie (NYSE: ABBV) reported that it will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 (Press release, AbbVie, JAN 2, 2024, View Source [SID1234638885]). Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D. senior vice president, development and regulatory affairs and chief medical officer, will present at 10:15 a.m. Central time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

On January 2, 2024 MediLink Therapeutics ("MediLink"), reported that it has entered into a worldwide collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors (Press release, Hoffmann-La Roche, JAN 2, 2024, View Source [SID1234638884]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of MediLink’s ADC asset, YL211. MediLink will work together with Roche’s R&D unit China Innovation Center of Roche (CICoR) to initiate the Phase I clinical trial of YL211 and Roche will then take over the further development and commercialization globally. MediLink will receive upfront and near-term milestone payments totaling $50 million and, together with additional development, regulatory and commercial milestone payments potentially reaching a total deal value nearing $1 billion, as well as tiered royalties on future global annual net sales.

About YL211

YL211 is a next-generation antibody-drug conjugate specifically targeting c-Mesenchymal-epithelial transition factor (c-Met), which belongs to the receptor tyrosine kinase (RTK) family. c-Met is closely associated with tumor formation, aggressive growth, and metastasis, making it a critical target for treating epithelial-mesenchymal transition. Despite c-Met targeting therapies including ADCs showing efficacy for patients with solid tumors, there remains an opportunity to address the significant unmet medical need for patients by providing a better treatment option worldwide. YL211, currently at IND stage, utilizes MediLink’s latest generation TMALIN ADC platform technology, along with a highly specific c-Met antibody. It has demonstrated promising efficacy and safety in various preclinical tumor models and safety evaluation experiments.

On January 2, 2024 Biohaven Ltd. (NYSE: BHVN) reported that Vlad Coric, M.D., Chairman and Chief Executive Officer, reported that it will present at the 42nd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Monday, January 8, 2024 at 8:15 am (PT) (Press release, Biohaven Pharmaceutical, JAN 2, 2024, View Source [SID1234638883]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A slide deck of the presentation will be available on the Investors section of the Biohaven website at www.biohaven.com.

On January 2, 2024 Allorion Therapeutics ("Allorion"), a US and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, reported that it has entered into an exclusive option and global license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC) (Press release, Allorion Therapeutics, JAN 2, 2024, View Source [SID1234638882]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, AstraZeneca will be granted an exclusive option to license a novel EGFR L858R allosteric inhibitor to develop and commercialize globally. Allorion is eligible to receive upfront and near-term payments of up to $40 million, and additional development and commercial milestone payments of over $500 million, as well as tiered royalties on net sales worldwide.

Fang Li, PhD., Cofounder and Chief Scientific Officer of Allorion remarked, "Allorion’s EGFR L858R allosteric inhibitor is designed to address mechanisms of resistance to current EGFR inhibitors and has the potential to enhance their activity, when used in combination. We are excited to enter into this agreement with AstraZeneca, a global leader in this field, to advance our EGFR inhibitor into the clinic and explore potential combinations with other EGFR targeting molecules such as Tagrisso."

On January 2, 2024 WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and IntoCell, a Korean biotechnology company dedicated to developing novel ADC platform technologies, reported that they have signed a Memorandum of Understanding (MOU) for a comprehensive partnership in drug-linker technology and CRDMO services spanning from discovery to commercialization (Press release, IntoCell, JAN 2, 2024, View Source [SID1234638881]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel Camptothecin drugs called NexatecansTM, a new class of OHPAS-able Camptothecins. WuXi XDC will provide fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services. This synergy will empower clients of both parties to accelerate PCC (Pre-clinical candidates) selection further, develop more next-generation ADCs and other bioconjugates, and expedite the CMC development process.

Dr. Jimmy Li, CEO of WuXi XDC, commented, "IntoCell’s unique drug-linker technologies and our leading, open-access platform are a great combination to enable the fast delivery of pre-clinical candidates, especially in novel ADC programs. We are delighted to reach this comprehensive partnership with IntoCell and to forge the capability synergy. It demonstrates WuXi XDC’s platform development strategy, namely to grow continually and evolve to help our clients to accelerate and transform the discovery, development and manufacturing of ADCs and other bioconjugates. "

Tae Kyo Park, Founder and CEO of IntoCell, commented, "Given WuXi XDC’s ample experience and superb capabilities in the CRDMO business, along with IntoCell’s proprietary drug-linker technology, the collaborative efforts of the two companies will pave an easier path for potential ADC development companies to access a variety of drug-linker sets in a stable yet fast-cleavable format. We are eager to witness positive progress towards that goal."